News
BRNS
0.5910
-1.48%
-0.0089
Weekly Report: what happened at BRNS last week (0803-0807)?
Weekly Report · 5d ago
Barinthus Biotherapeutics price target lowered to $6 from $7 at Alliance Global
TipRanks · 08/06 18:15
Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate
Benzinga · 08/06 12:42
Barinthus Biotherapeutics GAAP EPS of -$0.26
Seeking Alpha · 08/06 12:32
Weekly Report: what happened at BRNS last week (0727-0731)?
Weekly Report · 08/03 10:00
Weekly Report: what happened at BRNS last week (0720-0724)?
Weekly Report · 07/27 10:04
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/20 17:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 07/20 12:05
Weekly Report: what happened at BRNS last week (0713-0717)?
Weekly Report · 07/20 10:01
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 07/17 12:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/15 21:05
Weekly Report: what happened at BRNS last week (0706-0710)?
Weekly Report · 07/13 10:03
Weekly Report: what happened at BRNS last week (0629-0703)?
Weekly Report · 07/06 10:06
Weekly Report: what happened at BRNS last week (0622-0626)?
Weekly Report · 06/29 10:02
Weekly Report: what happened at BRNS last week (0615-0619)?
Weekly Report · 06/22 10:09
Weekly Report: what happened at BRNS last week (0608-0612)?
Weekly Report · 06/15 10:10
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/08 21:06
Weekly Report: what happened at BRNS last week (0601-0605)?
Weekly Report · 06/08 10:06
Weekly Report: what happened at BRNS last week (0525-0529)?
Weekly Report · 06/01 10:10
Weekly Report: what happened at BRNS last week (0518-0522)?
Weekly Report · 05/25 10:13
More
Webull provides a variety of real-time BRNS stock news. You can receive the latest news about Barinthus Biotherapeutics plc through multiple platforms. This information may help you make smarter investment decisions.
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.